 |
New EUDA vision for international cooperationThis month we are showcasing our new International Cooperation Framework (ICF), adopted by the EUDA Management Board in June. The ICF defines the agency’s vision and priorities for enhancing global collaboration on drug-related challenges. It follows the EUDA being given a stronger international role when it replaced the EMCDDA in July 2024. This new role strengthens our capacity to monitor and analyse the external dimension of the drugs problem and increase EU preparedness on drugs. EUDA Executive Director Alexis Goosdeel said: ‘The global nature of the drugs phenomenon requires global solutions. With this new framework, we are reaffirming our commitment to working hand in hand with partners across the world to strengthen our preparedness to deal with new challenges and address new threats. To do so, we will anticipate risks, share knowledge and build healthier and more secure communities’.
Read more >> | International cooperation >> | ICF >> |
|
|
Our COPOLAD III journey: building a stronger EU–LAC partnership on drugsWhen our contribution to the COPOLAD III programme wrapped up in March this year, it marked the end of nearly three years of the latest collaboration between the European Union and Latin America and Caribbean (LAC) countries in the drugs field. But the story doesn’t end there. This month, we're revisiting that journey and unveiling new resources. These include a summary of the project results and a video capturing its added value.
Read more >> | Summary >> | Video >> |
|
|
 |
Strategic foresight workshop on the future of synthetic drugs in Europe On 25 and 26 September, we hosted a strategic foresight workshop in Lisbon to explore potential scenarios for the future(s) of synthetic drugs in the EU by 2050. The event formed part of the ongoing EUDA project Synthetic drugs 2050: increasing EU resilience, which investigates how the availability and use of synthetic drugs in Europe might evolve by mid-century. The project is conducted under the EU’s Foresight-on-Demand framework (a mechanism designed to provide timely foresight input for policy-making), in co-production with the Futures Literacy Company (4CF) and the Finland Futures Research Centre (FFRC). The project combines horizon scanning with scenario development to assess emerging trends and signals of change. Its objective is, not only to anticipate potential health and public safety implications, but also to map out the political, societal, economic, legal, technological and environmental impacts of synthetic drugs. By doing so, it seeks to generate concrete policy, research and practice recommendations, while engaging key stakeholders in building resilient, future-proof responses. |
|
|
New EUDA foresight resources This month, we published new EUDA resources showcasing our work in the area of foresight, which are designed to support stakeholders in undertaking foresight studies. ➡️ EUDA foresight activities web page (new).
➡️ EUDA scenarios toolkit: how to run a scenario workshop for the drugs field (new).
➡️ EUDA horizon scanning toolkit: how to run a trends workshop for the drugs field (updated). |
|
|
EUROPEAN DAY OF LANGUAGES |
|
|
 |
Multilingualism at the heart of our workOn European Day of Languages (26 September), we celebrated the richness of Europe’s linguistic and cultural diversity. At the EUDA, multilingualism is at the heart of our work, helping us deliver evidence-based information on drugs to audiences across Europe — in their own languages.
Multilingualism and accessibility are key features of the EUDA’s new Communication Strategy 2025-2028. Communicating in languages other than English increases impact, while promoting plain language supports clarity and machine translation, thereby facilitating content creation in EU and non-EU languages. To make our work more user-friendly, we are increasingly integrating automatic translation capabilities in our digital services and products. This provides our customers with translated content, enabling them to share evidence and promote best practice nationally. With our growing international role, cultural adaptation of content is also key. Our focus on accessible, reusable formats ensures information reaches the widest audience, in line with EU accessibility and open data standards. The strategy is now available in 25 languages (23 EU + Norwegian and Turkish).
Read more >> | Communication Strategy >> |
|
|
European Drug Report 2025 — read it in your own language! To mark European Day of Languages this month, we are delighted to announce that the European Drug Report 2025 is now available in 25 languages. Based on data from 29 countries (EU 27, Türkiye and Norway), the online report delivers the latest overview of the drug situation in Europe, exploring long-term trends and emerging threats. The comprehensive analysis covers drug use and supply as well as drug-related harms and responses to them. The report contains dedicated interactive dashboards which allow users to visualise data and trends at European and national level. Users can generate PDFs of individual chapters or find topics of interest via a 'Search within the book' function.
Read more >> |
|
|
Multilingual glossary — supporting linguistic precision on drugs Looking for drug-related terms in different languages? Then take a look at our online Multilingual glossary, a practical tool aimed at ensuring high-quality and comparable content on drug-related topics in Europe. The glossary is the result of our collaboration with the Translation Centre for the Bodies of the European Union (CdT) and the Reitox national focal points. Its main purpose is to ensure that terminology in EUDA reports and outputs is harmonised across multiple language versions, maintaining linguistic precision. Originally available in all EU official languages, plus Norwegian and Turkish, the glossary has been expanded in recent years to include Arabic, Georgian and Russian to support our international cooperation activities. Read more >> |
|
|
EUDA manifesto — bringing our purpose closer to youWhen we became the EUDA in July 2024, we published a brand manifesto designed to inspire, motivate and connect with our customers. Available in 25 languages, our manifesto captures the essence of the agency and is a statement of our purpose and intent. Take a look!
Read more >> |
|
|
XI International conference on NPS — Register now!Have you registered for the XI International Conference on Novel Psychoactive Substances, taking place in Nice from 3-4 November? If not, take a look at the recently released programme, featuring over 50 presentations by leading international experts across multiple fields (e.g. public health, medicine, social sciences, policy and law). The lead organiser, the International Society for the Study of Emerging Drugs (ISSED), also encourages contributions to Emerging Trends in Drugs, Addictions and Health, a new ISSED Open Access journal. This journal provides a global platform for high-quality, multidisciplinary research, addressing critical and timely issues in the field of psychoactive substances, addictions and drug-related health. Programme >> | Register >> | Submit manuscript >> |
|
|
Scientific analyst | Early Warning SystemDo you think you can stay one step ahead of emerging drug threats?
We’re hiring a Scientific analyst (AD 6) to help operate and develop the EU Early Warning System on new psychoactive substances.
Your mission:
➡️ Detect and assess new psychoactive substances before they become a crisis.
➡️ Provide early warnings and risk assessments to protect public health.
➡️ Work with EU partners to keep Europe prepared and resilient.
📅 Deadline: 17 October 2025
Read more >> |
|
|
Scientific analyst | Health and social responses (treatment)We’re looking for a Scientific analyst (AD 6) to strengthen our work on health and social responses to drug-related problems, with a special focus on treatment and quality standards.
This role is based in the Substance use, harms and responses unit and involves:
➡️ Leading work on drug treatment quality and outcomes.
➡️ Coordinating the EU-QUALITY project on European service standards.
➡️ Developing tools, evidence syntheses and capacity-building initiatives.
➡️ Contributing to flagship EUDA products like the European Drug Report.
📅 Deadline: 24 October 2025
Read more >> |
|
|
|
